206 related articles for article (PubMed ID: 7666075)
1. Economic evaluation of a randomized clinical trial comparing vinorelbine, vinorelbine plus cisplatin, and vindesine plus cisplatin for non-small-cell lung cancer.
Smith TJ; Hillner BE; Neighbors DM; McSorley PA; Le Chevalier T
J Clin Oncol; 1995 Sep; 13(9):2166-73. PubMed ID: 7666075
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness analysis of three regimens using vinorelbine (Navelbine) for non-small cell lung cancer.
Hillner BE; Smith TJ
Semin Oncol; 1996 Apr; 23(2 Suppl 5):25-30. PubMed ID: 8610234
[TBL] [Abstract][Full Text] [Related]
3. Overview of economic analysis of Le Chevalier Vinorelbine Study.
Hillner BE; Smith TJ
Oncology (Williston Park); 1998 Mar; 12(3 Suppl 4):14-6; discussion 17. PubMed ID: 9556778
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of vinorelbine alone or vinorelbine plus cisplatin for stage IV NSCLC.
Evans WK
Oncology (Williston Park); 1998 Mar; 12(3 Suppl 4):18-25; discussion 25-6. PubMed ID: 9556779
[TBL] [Abstract][Full Text] [Related]
5. A three-arm trial of vinorelbine (Navelbine) plus cisplatin, vindesine plus cisplatin, and single-agent vinorelbine in the treatment of non-small cell lung cancer: an expanded analysis.
Le Chevalier T; Pujol JL; Douillard JY; Alberola V; Monnier A; Riviere A; Lianes P; Chomy P; Cigolari S; Besson F
Semin Oncol; 1994 Oct; 21(5 Suppl 10):28-33; discussion 33-4. PubMed ID: 7973766
[TBL] [Abstract][Full Text] [Related]
6. The cost-effectiveness of navelbine alone or in combination with cisplatin in comparison to other chemotherapy regimens and best supportive care in stage IV non-small cell lung cancer.
Evans WK; Le Chevalier T
Eur J Cancer; 1996 Dec; 32A(13):2249-55. PubMed ID: 9038606
[TBL] [Abstract][Full Text] [Related]
7. Vinorelbine plus cisplatin versus cisplatin plus vindesine and mitomycin C in stage IIIB-IV non-small cell lung carcinoma: a prospective randomized study.
Gebbia V; Galetta D; Riccardi F; Gridelli C; Durini E; Borsellino N; Gebbia N; Valdesi M; Caruso M; Valenza R; Pezzella G; Colucci G;
Lung Cancer; 2002 Aug; 37(2):179-87. PubMed ID: 12140141
[TBL] [Abstract][Full Text] [Related]
8. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients.
Le Chevalier T; Brisgand D; Douillard JY; Pujol JL; Alberola V; Monnier A; Riviere A; Lianes P; Chomy P; Cigolari S
J Clin Oncol; 1994 Feb; 12(2):360-7. PubMed ID: 8113844
[TBL] [Abstract][Full Text] [Related]
9. Vinorelbine in advanced non-small cell lung cancer. A pharmacoeconomic review.
Coukell AJ; Noble S; Faulds D
Pharmacoeconomics; 1999 Apr; 15(4):405-17. PubMed ID: 10537959
[TBL] [Abstract][Full Text] [Related]
10. Long term analysis of survival in the European randomized trial comparing vinorelbine/cisplatin to vindesine/cisplatin and vinorelbine alone in advanced non-small cell lung cancer.
Le Chevalier T; Brisgand D; Soria JC; Douillard JY; Pujol JL; Ruffie P; Aberola V; Cigolari S
Oncologist; 2001; 6 Suppl 1():8-11. PubMed ID: 11181998
[TBL] [Abstract][Full Text] [Related]
11. Decision framework for chemotherapeutic interventions for metastatic non-small-cell lung cancer.
Berthelot JM; Will BP; Evans WK; Coyle D; Earle CC; Bordeleau L
J Natl Cancer Inst; 2000 Aug; 92(16):1321-9. PubMed ID: 10944554
[TBL] [Abstract][Full Text] [Related]
12. [Cost-effectiveness analysis: a reader's guide].
Vergnenègre A
Rev Mal Respir; 2003 Feb; 20(1 Pt 1):116-25. PubMed ID: 12709640
[TBL] [Abstract][Full Text] [Related]
13. Economic analysis of a randomized phase III trial of gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer (Italian GEMVIN3/NCIC CTG BR14 trial).
Reaume MN; Leighl NB; Mittmann N; Coyle D; Hirsh V; Seymour L; Tu D; Shepherd FA; Graham B; Gridelli C; Perrone F; Di Maio M; Bradbury PA; Evans WK
Lung Cancer; 2013 Oct; 82(1):115-20. PubMed ID: 23962449
[TBL] [Abstract][Full Text] [Related]
14. Multicenter randomized trial comparing cisplatin-mitomycin-vinorelbine versus cisplatin-mitomycin-vindesine in advanced non-small cell lung cancer. 'Groupe Français de Pneumo-Cancérologie'.
Pérol M; Guérin JC; Thomas P; Poirier R; Carles P; Robinet G; Kleisbauer JP; Paillotin D; Vergnenègre A; Balmes P; Touron D; Grivaux M; Pham E
Lung Cancer; 1996 Feb; 14(1):119-34. PubMed ID: 8696715
[TBL] [Abstract][Full Text] [Related]
15. Cost analysis of hospital treatment--two chemotherapic regimens for non-surgical non-small cell lung cancer. GFPC (Groupe Français Pneumo Cancérologie).
Vergnenègre A; Perol M; Pham E
Lung Cancer; 1996 Feb; 14(1):31-44. PubMed ID: 8696719
[TBL] [Abstract][Full Text] [Related]
16. Economic analysis of vinorelbine plus cisplatin versus paclitaxel plus carboplatin for advanced non-small-cell lung cancer.
Ramsey SD; Moinpour CM; Lovato LC; Crowley JJ; Grevstad P; Presant CA; Rivkin SE; Kelly K; Gandara DR
J Natl Cancer Inst; 2002 Feb; 94(4):291-7. PubMed ID: 11854391
[TBL] [Abstract][Full Text] [Related]
17. Economic analysis of NCIC CTG JBR.10: a randomized trial of adjuvant vinorelbine plus cisplatin compared with observation in early stage non-small-cell lung cancer--a report of the Working Group on Economic Analysis, and the Lung Disease Site Group, National Cancer Institute of Canada Clinical Trials Group.
Ng R; Hasan B; Mittmann N; Florescu M; Shepherd FA; Ding K; Butts CA; Cormier Y; Darling G; Goss GD; Inculet R; Seymour L; Winton TL; Evans WK; Leighl NB; ; ;
J Clin Oncol; 2007 Jun; 25(16):2256-61. PubMed ID: 17538170
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness analysis: sleeping with an enemy or a friend?
Gulati SC; Bitran JD
J Clin Oncol; 1995 Sep; 13(9):2152-4. PubMed ID: 7666072
[No Abstract] [Full Text] [Related]
19. Cost-effectiveness of continuation maintenance pemetrexed after cisplatin and pemetrexed chemotherapy for advanced nonsquamous non-small-cell lung cancer: estimates from the perspective of the Chinese health care system.
Zeng X; Peng L; Li J; Chen G; Tan C; Wang S; Wan X; Ouyang L; Zhao Z
Clin Ther; 2013 Jan; 35(1):54-65. PubMed ID: 23328269
[TBL] [Abstract][Full Text] [Related]
20. Cost-Effectiveness and Value of Information of Erlotinib, Afatinib, and Cisplatin-Pemetrexed for First-Line Treatment of Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer in the United States.
Ting J; Tien Ho P; Xiang P; Sugay A; Abdel-Sattar M; Wilson L
Value Health; 2015 Sep; 18(6):774-82. PubMed ID: 26409604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
